MedWatch

New chairman candidate says Sobi will be revitalized

Bo Jesper Hansen has been tapped to chair Sweden’s biggest pharmaceutical firm, which he founded in the early 90s. In the role, he will fulfil desires for a long-term strategy, he says.

Photo: John Ambrose / Sobi / PR

Bo Jesper Hansen is heading back to Sobi, a company he helped found in 1991, after being nominated for the chairman role of the company. In and interview with Danish business daily Børsen, he says his goal is making Sobi the world leader within rare diseases following some failed acquisitions attempts from private equity firms Advent and GIC, last year.

”After the takeover attempts, shareholders have wished for a more long-term strategy to revitalize and refocus the company. As leader, that’s what I will do,” he tells the media.

As chairman, Hansen will have much responsibility for Sweden’s biggest pharmaceutical firm, which employs around 1,600 people, has a market value of approximately DKK 45bn (USD 6.2bn), and a revenue of DKK 10.5bn (USD 1.4bn).

Håkan Björklund, Sobi’s former chair, announced in October he would not seek re-election at the company’s next annual general meeting, which is slated for May 2023.

Sobi taps founder for chairman position

Orphazyme halves board of directors – chair not up for reelection

Sobi co-founder thinks acquisition is likely after USD 8bn bid

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs